Markers associated with arteriovascular events and methods of use thereof
View Patent ↗Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.
1. A method for treating an asymptomatic cardiovascular subject or a previously undiagnosed cardiovascular subject determine to be at risk for a future arteriovascular event or disease comprising:
providing a blood sample isolated from an asymptomatic cardiovascular subject or a previously undiagnosed cardiovascular subject;
measuring at least four component ARTERIORISKMARKERS in the blood sample selected from one or more groups consisting of Core Markers I, Core Markers II, Traditional Laboratory Risk Factors, Supplemental Markers I, Supplemental Markers II, Additional Markers I, and Additional Markers II, wherein at least one component ARTERIORISKMARKER is adiponectin;
calculating an index value from an output of a Support Vector Machine (SVM) model, wherein inputs to the model comprise the measurements, and further wherein the model was developed by fitting data from a longitudinal study of a selected population of individuals and the fitted data comprises levels of the biomarkers and an end point in the selected population of individuals, wherein a calculated area under the curve (AUC) of the model is greater than or equal to 0.70, and wherein the end point is the risk of the cardiovascular event or the cardiovascular event; and
administering to the subject a therapeutic or prophylactic agent.
2. The method of claim 1 , wherein the index value is correlated with the risk of the cardiovascular event or the cardiovascular event.
3. The method of claim 2 , wherein the risk evaluation comprises normalizing the component ARTERIORISKMARKER measurements to reference values.
4. The method of claim 1 , further comprising measuring at least two component ARTERIORISKMARKERS within Core Markers I.
5. The method of claim 1 , further comprising measuring at least two component ARTERIORISKMARKERS within Core Markers II.
6. The method of claim 1 , further comprising measuring at least two component ARTERIORISKMARKERS within Traditional Laboratory Risk Factors.
7. The method of claim 1 , further comprising measuring at least two component ARTERIORISKMARKERS within Clinical Parameters.
8. The method of claim 1 , further comprising measuring at least two component ARTERIORISKMARKERS within Supplemental Markers I or Supplemental Markers II.
9. The method of claim 1 , further comprising measuring at least two component ARTERIORISKMARKERS within Additional Markers I or Additional Markers II.
10. The method of claim 1 , wherein the measurement of at least one of the biomarkers of the panel is unaffected by treatment of the subject with one or more therapeutic interventions.
11. The method of claim 1 , wherein the measurement of at least one of the biomarkers of the panel is affected by treatment of the subject with one or more therapeutic interventions.
12. The method of claim 1 , further comprising measuring or determining one or more clinical parameters chosen from age, body mass index (BMI), diabetes, diastolic blood pressure (DBP), family history (FamHX), hip (circumference), height (HT), ethnicity (RACE), systolic blood pressure (SBP), gender (SEX), smoking, waist (circumference), and weight (WT).
13. The method of claim 1 , further comprising one or more additional biomarker chosen from POMC, HDLC, and VEGF.
14. A method for treating an asymptomatic cardiovascular subject or a previously undiagnosed cardiovascular subject comprising:
administering to the subject a therapeutic or prophylactic agent, wherein the subject has been determined to be at risk of developing arteriovascular disease or a arteriovascular event by a method comprising:
measuring at least four component ARTERIORISKMARKERS in the blood sample selected from one or more groups consisting of Core Markers I, Core Markers II, Traditional Laboratory Risk Factors, Supplemental Markers I, Supplemental Markers II, Additional Markers I, and Additional Markers II, wherein at least one component ARTERIORISKMARKER is adiponectin; and
calculating an index value from an output of a Support Vector Machine (SVM) model, wherein inputs to the model comprise the measurements, and further wherein the model was developed by fitting data from a longitudinal study of a selected population of individuals and the fitted data comprises levels of the biomarkers and an end point in the selected population of individuals, wherein a calculated area under the curve (AUC) of the model is greater than or equal to 0.70, and wherein the end point is the risk of the cardiovascular event or the cardiovascular event.